Disc Medicine, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY

Common Stock$0.0001 Par Value · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income	Deficit	Equity
Balance at December 31, 2022	17,403,315	$2	$288,814	$—	$(112,216)	$176,600
Issuance of common stock upon exercise of stock options	254,432	—	2,763	—	—	2,763
Issuance of common stock upon vesting of restricted stock awards	1,916	—	—	—	—	—
Issuance of common stock upon exercise of warrants	1,229,221	—	—	—	—	—
Sale of common stock in follow-on public offering, net of issuance costs of $9,272	3,015,919	—	138,508	—	—	138,508
Sale of pre-funded warrants in follow-on public offering, net of issuance costs of $627	—	—	9,373	—	—	9,373
Sale of common stock in underwritten offering, net of issuance costs of $80	1,488,166	—	34,148	—	—	34,148
Sale of pre-funded warrants in underwritten offering, net of issuance costs of $66	—	—	28,206	—	—	28,206
Sale of common stock in at-the-market offerings, net of issuance costs of $742	967,264	—	26,422	—	—	26,422
Stock-based compensation expense	—	—	5,530	—	—	5,530
Net loss	—	—	—	—	(76,429)	(76,429)
Balance at December 31, 2023	24,360,233	$2	$533,764	$—	$(188,645)	$345,121
Issuance of common stock upon exercise of stock options	315,266	—	2,976	—	—	2,976
Issuance of common stock under employee stock purchase plan	11,082	—	441	—	—	441
Sale of common stock in an underwritten offering, net of issuance costs of $5,472	4,944,000	1	172,511	—	—	172,512
Sale of common stock in at-the-market offerings, net of issuance costs of $518	234,449	—	14,790	—	—	14,790
Stock-based compensation expense	—	—	16,815	—	—	16,815
Foreign currency translation adjustments	—	—	—	(27)	—	(27)
Unrealized gain on marketable securities	—	—	—	316	—	316
Net loss	—	—	—	—	(109,357)	(109,357)
Balance at December 31, 2024	29,865,030	$3	$741,297	$289	$(298,002)	$443,587
Issuance of common stock upon exercise of stock options	578,872	—	8,641	—	—	8,641
Issuance of common stock upon vesting of restricted stock units	117,911	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	14,115	—	578	—	—	578
Sale of common stock in underwritten offerings, net of issuance costs of $28,978	7,152,231	—	440,346	—	—	440,346
Sale of pre-funded warrants in underwritten offerings, net of issuance costs of $925	—	—	14,076	—	—	14,076
Sale of common stock in at-the-market offering, net of issuance costs of $302	162,457	1	9,765	—	—	9,766
Stock-based compensation expense	—	—	34,340	—	—	34,340
Foreign currency translation adjustments	—	—	—	(1)	—	(1)
Unrealized gain on marketable securities	—	—	—	677	—	677
Net loss	—	—	—	—	(212,184)	(212,184)
Balance at December 31, 2025	37,890,616	$4	$1,249,043	$965	$(510,186)	$739,826

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.